Based in Australia, RoseRx is a digital health company specializing in patient activation and engagement platforms tailored for the life sciences sector. The company offers a patient-centric, clinical-first platform designed to improve healthcare outcomes by enhancing patient engagement through digital channels. Its platform connects patients and healthcare providers both online and in-person, creating an end-to-end personalized healthcare journey for users, leading to better health outcomes.
Key customers and partnerships
RoseRx serves various stakeholders in the healthcare and life sciences industries, including life sciences companies, healthcare providers, and marketing agencies. Some of its clients are Unilever, Baxter, DiDi, MSD, and Novo Nordisk.
Funding and Financials
In September 2021, RoseRx raised approximately AUD 6.6 million (USD 4.86 million) in a Series A funding round led by Breyer Capital. The intended use of the funds was undisclosed.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.